Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients

This trial is testing whether adding an immunotherapy drug called camrelizumab to standard chemotherapy after surgery helps prevent non-small cell lung cancer (NSCLC) from coming back in patients with stage IIA–IIIA disease who cannot use targeted therapy. **You may be eligible if...** - You are 18–80 years old - You have had surgery for non-small cell lung cancer at stage IIA–IIIA - You are not eligible for targeted therapy (e.g., your tumor does not have EGFR, ALK, or similar mutations that have approved targeted drugs) - You have not had chemotherapy for lung cancer before - You have recovered from surgery and are ready for treatment within 3–8 weeks - Your ECOG performance status is 0 or 1 (you are fairly active and independent) - Your blood counts, liver, and kidney function are adequate **You may NOT be eligible if...** - You are eligible for targeted therapy - You have had another cancer in the past 5 years (with some exceptions like cured skin or cervical cancers) - You have had a heart attack, serious heart condition, or uncontrolled high blood pressure recently - You have active HIV, hepatitis B, or hepatitis C - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.